Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?

医学 2型糖尿病 药方 糖尿病 内科学 优势比 疾病 利拉鲁肽 逻辑回归 内分泌学 药理学
作者
Sebastian Barth,Karel Kostev,Magdalene Krensel,Elke Mathey,Wolfgang Rathmann
出处
期刊:Experimental and Clinical Endocrinology & Diabetes [Thieme Medical Publishers (Germany)]
卷期号:131 (03): 153-161 被引量:1
标识
DOI:10.1055/a-1927-4454
摘要

Abstract Objectives To analyze whether prescription use of GLP-1RA and SGLT2i in individuals with type 2 diabetes with cardiovascular disease (CVD) has increased after the ADA/EASD consensus guidelines (2018) in a German Real-World setting and which clinical characteristics are associated with prescription use of these drugs. Methods The Disease Analyzer database (IQVIA) comprises a representative panel of 1,373 general practitioners, diabetologists, and cardiologists throughout Germany (01/2015-12/2020: 12.6 million patients). Newly diagnosed type 2 diabetes (n=45,531) was identified by ICD-10 codes (E11). Matching (1:1) on practice specialty, sex, age, and year of diabetes diagnosis was performed for CVD. Logistic regression models were fitted to obtain adjusted odds ratios (OR) for characteristics associated with prescription use (median follow-up: 1.9 years). Results Overall, 35% of patients (n=16,006) were treated with glucose-lowering drugs during the first year after type 2 diabetes diagnosis (HbA1c≥7.0%: 80%). GLP-1RA (2.4%) and SGLT2i (8.5%) were rarely prescribed. After the consensus, use of GLP-1RA and SGLT2i increased, however, almost independently of pre-existing CVD (12/2019-11/2020 vs. 12/2017-11/2018: yes, no): GLP-1RA: from 5.7 to 9.2%, 5.2 to 7.6%; SGLT2i: from 13.9 to 20.4%, 12.1 to 16.6%. Among cardiovascular risk factors, the largest OR for GLP-1RA was for obesity (4.5; 95%CI: 3.2–6.3). CVD was moderately related with SGLT2i (1.45; 1.32–1.60) and GLP-1RA (1.35; 1.08–1.69) prescriptions. A weak association was observed between SGLT2i and heart failure (1.18; 95%CI: 1.05–1.32). Conclusion National prescription use of GLP-1RA and SGLT2i did not come close to the recommendation in subjects with CVD issued by the 2018 ADA/EASD consensus.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shenglll完成签到 ,获得积分10
3秒前
量子星尘发布了新的文献求助10
4秒前
普鲁卡因发布了新的文献求助10
9秒前
Liang完成签到,获得积分10
10秒前
爱思考的小笨笨完成签到,获得积分10
11秒前
123456完成签到 ,获得积分10
11秒前
小飞完成签到 ,获得积分10
12秒前
俞斐完成签到,获得积分10
13秒前
我超爱cs完成签到,获得积分10
13秒前
爱因斯坦那个和我一样的科学家完成签到,获得积分10
20秒前
彭a完成签到,获得积分10
20秒前
Migrol完成签到,获得积分10
21秒前
高兴的小完成签到,获得积分10
21秒前
蕉鲁诺蕉巴纳完成签到,获得积分0
23秒前
慕青应助普鲁卡因采纳,获得10
23秒前
御剑乘风来完成签到,获得积分10
23秒前
李牛牛完成签到,获得积分10
27秒前
等待的代容完成签到,获得积分10
29秒前
传奇3应助小南孩采纳,获得10
29秒前
尊敬飞丹完成签到,获得积分10
30秒前
32秒前
离岸完成签到,获得积分10
32秒前
tian完成签到,获得积分10
34秒前
普鲁卡因发布了新的文献求助10
36秒前
daijk完成签到,获得积分10
37秒前
39秒前
风趣的烨磊完成签到,获得积分10
42秒前
仝富贵完成签到,获得积分10
43秒前
小南孩发布了新的文献求助10
44秒前
奔铂儿钯完成签到,获得积分10
45秒前
跳跃山柳完成签到,获得积分10
47秒前
量子星尘发布了新的文献求助10
49秒前
小南孩完成签到,获得积分10
52秒前
脑洞疼应助普鲁卡因采纳,获得10
58秒前
zhaoyaoshi完成签到 ,获得积分10
58秒前
chiazy完成签到,获得积分10
59秒前
智慧金刚完成签到 ,获得积分10
59秒前
汉堡包应助科研通管家采纳,获得10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
59秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022